Published: July 2020 | Report Code: LS12048 | Available Format: PDF | Pages: 266
The autoimmune disease diagnostics market revenue stood at $4,086.2 million in 2019, and the market is predicted to register a CAGR of 8.5% between 2020 and 2030. The discovery of new biomarkers, increasing number of strategic development activities among major players, growing incidence of autoimmune diseases, and implementation of initiatives by various private and public organizations for raising awareness about autoimmune diseases are the major factors fueling the expansion of the market across the globe.
The consumables and assay kits category had the larger share in the autoimmune disease diagnostics industry during 2014–2019, under the product segment. This category is predicted to continue its market domination in the future on account of the existence of numerous industry players providing diagnostic test kits. Additionally, the growing prevalence of autoimmune diseases and increasing number of research activities for identifying their underlying causes are driving the advance of the market.
Out of the routine laboratory, autoantibodies and immunology, inflammatory marker, cytokine, human leukocyte antigen (HLA), and flow cytometry test types, the routine laboratory category contributed the highest revenue in 2019. This category is also predicted to hold the largest share and register the fastest growth in the autoimmune disease diagnostics market in the forthcoming years. This is credited to the fact that serum tests and blood tests are initial procedures, and they need to be conducted multiple times for checking for abnormalities in the bloodstream.
The RA category, under the application segment, is predicted to demonstrate the fastest growth in the market for autoimmune disease diagnostics solutions in the coming years because of the high incidence of RA all over the world. In the Global Burden of Diseases (GBD) 2017 report, the worldwide prevalence of RA is mentioned in detail. As per the statistical data, there were 10,226,042 global cases of RA in 1990, and this number grew to 19,965,115 in 2017.
Hospitals Generating Highest Revenue
Hospitals generated the highest revenue in the market in 2019, under the end user segment. This category is also predicted to hold the largest market share till 2030. This is attributed to the growing usage of technologically advanced products, rising incidence of chronic autoimmune diseases, increasing number of conferences and awareness campaigns conducted by private and public organizations, and rapidly improving healthcare infrastructure around the world.
North America had the largest share in the autoimmune disease diagnostics market from 2014 to 2019 because of the soaring healthcare spending, growing incidence of autoimmune diseases, surging population of geriatric people, and existence of prominent industry players in the region.
As per an article produced by the National Institute of Environmental Health Sciences (NIEHS), one of the 27 National Institutes of Health (NIH), in May 2020, as many as 80 autoimmune diseases are currently known in North America, including multiple sclerosis, type-1 diabetes, RA, and systemic lupus erythematosus (SLE). Out of these, some are extremely rare and tough to diagnose. In the U.S., nearly 24 million people were diagnosed with autoimmune diseases in 2019. Additionally, nearly 8 million people in the country have autoantibody blood molecules, which can cause autoimmune diseases later in life.
The existence of major players is one of the key factors fueling the demand for autoimmune disease diagnostic solutions in the APAC region. Besides this, the availability of cheap labor and cost-effective diagnostic tests, surging geriatric population, and initiatives by private and public entities for raising awareness about autoimmune diseases are positively impacting the autoimmune disease diagnostics market growth in the region. As per the World Bank’s data, the share of people aged 65 years and above in the total population of Japan grew from 22.5% in 2010 to 27.6% in 2018. Furthermore, this share is predicted to rise to 60.0% by 2030, with similar scenarios predicted in other APAC nations.
The COVID-19 pandemic is positively impacting the market for autoimmune disease diagnostics growth. The pandemic has massively pushed up the requirement for diagnostic products all over the world. Moreover, the market is set for lucrative growth once the lockdowns are lifted and export and import activities resume.
One of the major trends currently being witnessed in the market is the discovery of new biomarkers for diagnosing autoimmune diseases. For example, researchers working at the University of Alberta identified a new biological marker for identifying the existence of myasthenia gravis, which is a rare autoimmune disease, in August 2019. This biomarker can also be used for predicting the course of the disease and formulating new personalized treatment procedures.
Another important factor fueling the progress of the autoimmune disease diagnostics market is the growing awareness about autoimmune diseases. For example, in Athens, Greece, the 12th International Congress on Autoimmunity will be held from November 28, 2020, to December 1, 2020. Similarly, several conferences are predicted to be held all over the world throughout 2021 for making people aware of the technological advancements being made in the domain of autoimmune disease diagnosis and treatment.
For instance, in Rome, Italy, the International Conference on Autoimmune Diseases and Dermatology will be held from January 18 to January 19, 2021. These conferences bring together numerous researchers, research scholars, and academic scientists for exchanging thoughts and sharing their experiences and research results on the different aspects of autoimmune diseases.
The rising incidence of autoimmune diseases is also adding wings to the market advance across the world. As per the Johns Hopkins University, nearly 3% of the people of the U.S. are affected by autoimmune diseases every year. This means that such health issues affect around 10 million people in the country. Furthermore, as per a report produced by the Myasthenia Gravis Foundation of America in June 2015, 14–20 individuals out of every 100,000 people, or around 36,000–60,000 people, in the U.S. were affected with myasthenia gravis in 2014.
|Base Year (2019) Market Size||$4,086.2 million|
|Forecast Period (2020-2030) CAGR||8.5%|
|Report Coverage||Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies’ Strategical Developments, Product Benchmarking, Company Share Analysis, Company Profiling|
|Market Size by Segments||Product, Test Type, Application, End User, Region|
|Market Size of Geographies||U.S., Canada, Germany, France, Italy, U.K., Spain, Japan, China, India, Brazil, Mexico, Saudi Arabia, South Africa, Israel, U.A.E.|
|Secondary Sources and References (Partial List)||Centers for Disease Control and Prevention (CDC), Organisation for Economic Co-operation and Development (OECD), World Health Organization (WHO), American Heart Association (AHA), United States Food and Drug Administration (USFDA), National Institute of Environmental Health Sciences (NIEHS), American Autoimmune Related Diseases Association, National Institute for Health and Care Excellence (NICE) Note: Above listed references and organizations are partial; the detailed and complete list is available in the final report.|
The market for autoimmune disease diagnostics is consolidated in nature, with the presence of market players including Abbott Laboratories, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Siemens AG, Grifols S.A., Danaher Corporation, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., and bioMérieux S.A.
In recent years, the players in the industry have engaged in strategic developments, such as product launches, in order to stay ahead of their competitors. For instance:
The autoimmune disease diagnostics market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
The autoimmune disease diagnostics market generated revenue of $4,086.2 million in 2019.
The autoimmune disease diagnostics industry will grow by 8.5% during 2020–2030.
The advent of novel biomarkers for diagnosis is the prominent trend in the autoimmune disease diagnostics market.
The surging public awareness of autoimmune diseases is the biggest growth driver of the autoimmune disease diagnostics industry.
Routine laboratory tests are the most widely performed in the autoimmune disease diagnostic market.
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws